Biotech Sisterhood Event
23rd Floor
San Francisco, CA 94105
Event summary
Given the heightened volatility in the equity markets, J.P. Morgan and Cooley hosted the Biotech Sisterhood event, with several panel discussions covering equity capital markets and M&A activity and outlook, as well as key considerations, preparation and execution of dual-track processes. A networking reception followed for those who attended in person in San Francisco.
Agenda
2:00 pm: Check in
2:15 – 4:30 pm: Panel discussions (includes Zoom participants)
4:30 – 5:30 pm: Cocktail reception
Featured agenda items
2:50 pm PDT
Biotech Equity Capital Markets Update
Cooley partner Kristin VanderPas joined J.P. Morgan’s Ben Burdett and Josh Bleharski to discuss the current state of the biotech equity capital markets.
Speakers
- Ben Burdett – Head of healthcare equity capital markets, J.P. Morgan
- Josh Bleharski – Global co-head of biopharma investment banking, J.P. Morgan
- Kristin VanderPas – Partner, Cooley
3:20 pm PDT
Biopharma M&A Environment Update
Cooley partner Ben Beerle joined J.P. Morgan’s Mike Gaito and Parul Jhunjhunwala to discuss the current state of dealmaking in the biopharma M&A space.
Speakers
- Mike Gaito – Global head of healthcare investment banking, J.P. Morgan
- Parul Jhunjhunwala – Executive director, M&A, J.P. Morgan
- Ben Beerle – Partner, Cooley
3:50 pm PDT
Dual-Track (IPO/M&A) Processes and a Case Study (Carmot Therapeutics)
Cooley partner Dave Peinsipp moderated a panel discussion about the dual-track process, which highlighted the key differences between acquisitions and initial public offerings (IPOs) and delved into strategic perspectives, managing expectations and information flow with potential acquirers, along with board dynamics.
Speakers
- Heather Turner – Former CEO of Carmot Therapeutics
- Ben Carpenter – Co-head of North America M&A, J.P. Morgan
- Dave Peinsipp – Partner and co-chair of global capital markets, Cooley
For more information, please email Erica Koljonen.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.